Promoting Recognition, Diagnosis, and Treatment of Cold Agglutinin Disease

TARGET AUDIENCE:
This activity was developed for adult hematologists, hematologist-oncologists, hematology-oncology nurse practitioners, emergency physicians, primary care physicians, and other clinicians involved in the management of patients with cold agglutinin disease.
PROGRAM OVERVIEW:
Cold Agglutinin Disease is a rare, chronic hemolytic disorder, representing approximately 20% of all autoimmune hemolytic anemias. Catherine M. Broome, MD, and Alexander Röth, MD, provide an understanding of the pathogenesis of this disorder caused by cold-reacting IgM autoantibodies and reveal common clinical features. Because of the high mortality rate among those suffering from CAD, it is important to be aware of the diagnostic criteria, as well as the current and novel treatment options, with the goal of increasing hemoglobin levels, avoiding the need for transfusions, and improving circulatory symptoms. Dr. Broome discusses the most recent advancements in treatment based on global collaborative efforts and the importance of participating in the CADENCE Registry. Significant findings from the phase 3 CARDINAL trial are also presented along with an interactive case scenario.